<?xml version='1.0' encoding='utf-8'?>
<document id="27226420"><sentence text="Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives." /><sentence text="1" /><sentence text="窶ケanobinostat is a recently approved histone deacetylase (HDAC) inhibitor"><entity charOffset="1-13" id="DDI-PubMed.27226420.s3.e0" text="Panobinostat" /></sentence><sentence text=" 2" /><sentence text="窶サhe pharmacokinetic data of panobinostat in patients with hematologic malignancies and advanced solid tumors have been collated and reviewed from the various published clinical studies for over a decade"><entity charOffset="29-41" id="DDI-PubMed.27226420.s5.e0" text="panobinostat" /></sentence><sentence text=" Further perspectives and anticipated challenges in the clinical therapy with panobinostat are discussed in the review"><entity charOffset="78-90" id="DDI-PubMed.27226420.s6.e0" text="panobinostat" /></sentence><sentence text=" 3" /><sentence text="窶コegardless of intravenous or oral dosing, panobinostat showed a high degree of inter-patient variability in the pharmacokinetics" /><sentence text=" After oral administration, most of the administered dose is extensively metabolized and the metabolites are either fecally or renally excreted with trace amount of intact panobinostat"><entity charOffset="172-184" id="DDI-PubMed.27226420.s9.e0" text="panobinostat" /></sentence><sentence text=" Both cytochrome p450 (CYP) 3A4 and non-CYP mechanisms govern the clearance of panobinostat"><entity charOffset="79-91" id="DDI-PubMed.27226420.s10.e0" text="panobinostat" /></sentence><sentence text=" CYP3A4-related drug-drug interactions with panobinostat have been documented with ketoconazole (inhibitor) and dexamethasone (inducer)"><entity charOffset="44-56" id="DDI-PubMed.27226420.s11.e0" text="panobinostat" /><entity charOffset="83-95" id="DDI-PubMed.27226420.s11.e1" text="ketoconazole" /><entity charOffset="112-125" id="DDI-PubMed.27226420.s11.e2" text="dexamethasone" /><pair ddi="false" e1="DDI-PubMed.27226420.s11.e0" e2="DDI-PubMed.27226420.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27226420.s11.e0" e2="DDI-PubMed.27226420.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27226420.s11.e0" e2="DDI-PubMed.27226420.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27226420.s11.e1" e2="DDI-PubMed.27226420.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27226420.s11.e1" e2="DDI-PubMed.27226420.s11.e2" /></sentence><sentence text=" 4" /><sentence text="窶オn summary, the clinical pharmacokinetic data of panobinostat, a promising HDAC inhibitor, obtained from various clinical studies do not appear to limit the utility of panobinostat in the clinic" /><sentence text="" /></document>